Newborn affected by maternal use of other drugs of addiction
ICD-10 P04.49 is a billable code used to indicate a diagnosis of newborn affected by maternal use of other drugs of addiction.
P04.49 refers to newborns who are affected by maternal use of drugs of addiction that are not classified under specific categories such as opioids or alcohol. This includes a range of substances that may be transmitted to the fetus through the placenta or to the infant through breast milk. The clinical implications can vary widely, including withdrawal symptoms, developmental delays, and other health complications. Newborns may present with irritability, feeding difficulties, and abnormal neurological signs. The management of these infants often requires a multidisciplinary approach, including neonatologists, pediatricians, and social services, to address both the medical and psychosocial needs of the family. Accurate coding is essential for appropriate treatment planning and resource allocation.
Detailed maternal substance use history, newborn assessment findings, and treatment plans.
Newborns presenting with withdrawal symptoms in the NICU, requiring monitoring and supportive care.
Consideration of the timing of maternal drug use during pregnancy and its impact on neonatal outcomes.
Comprehensive developmental assessments and follow-up care plans for affected newborns.
Pediatric evaluations of infants with developmental delays linked to maternal substance use.
Long-term follow-up for developmental milestones and potential behavioral issues.
Used for newborns requiring evaluation and management due to maternal substance use.
Detailed history and physical examination findings.
Neonatologists should document specific assessments related to withdrawal symptoms.
Documentation must include a detailed maternal history of substance use, clinical assessments of the newborn, and any treatment provided. It is crucial to link the newborn's symptoms to maternal drug use.
